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Abstract 
Background: Major depressive disorder is a common psychiatric disorder causing great burden on patients and 
societies. Tricyclic antidepressants are frequently used worldwide to treat patients with major depressive disorder. It 
has repeatedly been shown that tricyclic antidepressants reduce depressive symptoms with a statistically significant 
effect, but the effect is small and of questionable clinical importance. Moreover, the beneficial and harmful effects of 
all types of tricyclic antidepressants have not previously been systematically assessed. Therefore, we aim to investigate 
the beneficial and harmful effects of tricyclic antidepressants versus ‘active placebo’, placebo or no intervention for 
adults with major depressive disorder.
Methods: This is a protocol for a systematic review with meta-analysis that will be reported as recommended by Pre-
ferred Reporting Items for Systematic Reviews and Meta-Analysis Protocols, bias will be assessed with the Cochrane 
Risk of Bias tool—version 2, our eight-step procedure will be used to assess if the thresholds for clinical significance 
are crossed, Trial Sequential Analysis will be conducted to control random errors and the certainty of the evidence will 
be assessed with the Grading of Recommendations Assessment, Development and Evaluation approach. To identify 
relevant trials, we will search both for published and unpublished trials in major medical databases and trial registers, 
such as CENTRAL, MEDLINE, EMBASE and ClinicalTrials.gov from their inception to 12 May 2021. Clinical study reports 
will be applied for from regulatory authorities and pharmaceutical companies. Two review authors will independently 
screen the results from the literature searches, extract data and perform risk of bias assessment. We will include any 
published or unpublished randomised clinical trial comparing tricyclic antidepressants with ‘active placebo’, placebo 
or no intervention for adults with major depressive disorder. The following interventions will be assessed: amineptine, 
amitriptyline, amoxapine, butriptyline, cianopramine, clomipramine, desipramine, demexiptiline, dibenzepin, dosule-
pin, dothiepin, doxepin, imipramine, iprindole, lofepramine, maprotiline, melitracen, metapramine, nortriptyline, 
noxiptiline, opipramol, protriptyline, tianeptine, trimipramine and quinupramine. Primary outcomes will be depressive 
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Background
Description of the condition
Major depressive disorder is a psychiatric condition char-
acterised by depressed mood and diminished interest 
or pleasure [1]. Major depressive disorder is associated 
with cognitive deficits leading to functional and occupa-
tional impairment [2]. The prevalence of major depres-
sive disorder is estimated to be more than 264 million 
people globally, making it one of the leading contributors 
to functional disability [3]. Additionally, the high preva-
lence of major depressive disorder leads to an extensive 
economic burden estimated at more than 210 billion US 
dollars annually in the US alone, deriving from direct 
medical costs as well as costs related to occupational 
disability and comorbidities [4]. Furthermore, major 
depressive disorder is associated with an increased risk 
of suicidal behaviour, with an estimated 15% of patients 
having attempted suicide at least once in their lifetime 
[5–7].
Description of interventions
Tricyclic antidepressants are a group of first-genera-
tion antidepressants commonly used for treating major 
depressive disorder, obsessive–compulsive disorder and 
chronic pain [8, 9]. The first tricyclic antidepressant, 
imipramine, was developed in the 1950s by modifying 
the phenothiazine ring and substituting sulphur with an 
ethylene bridge [9]. The majority of tricyclic antidepres-
sants function as serotonin and norepinephrine reuptake 
reuptake inhibitors [10, 11]. By blocking the reuptake of 
monoamine neurotransmitters in the presynaptic neu-
ron, tricyclic antidepressants theoretically increase the 
levels of serotonin and norepinephrine in the synaptic 
cleft [10, 12]. However, the role of monoamines in major 
depression is unclear and the exact mechanism of action 
of tricyclic antidepressants is uncertain [10, 13–15].
Whilst selective serotonin reuptake inhibitors are gen-
erally recommended as first-line treatment for major 
depressive disorder, tricyclic antidepressants are amongst 
recommended treatments for patients whose condition 
does not improve after treatment with newer medications 
[16–18]. The World Health Organisation Model List of 
Essential Medicines includes the tricyclic antidepressant 
amitriptyline as one of just two essential antidepressants 
for the treatment of major depressive disorder [19].
Why is it important to do this review?
Several systematic reviews with meta-analysis have 
assessed the beneficial effects of tricyclic antidepressants 
and have concluded that tricyclic antidepressants reduce 
depressive symptoms with a statistically significant effect 
for patients with major depressive disorder [20–23]. 
Some systematic reviews have concluded that tricyclic 
antidepressants, either as a drug class [20] or as an indi-
vidual drug [21], are indeed the most effective antide-
pressants [20, 21]. However, the effect sizes of tricyclic 
antidepressants were small and may not be important 
to the average patient [24]. Furthermore, trials compar-
ing antidepressants with ‘active placebo’ (a placebo that 
mimics the adverse effects of the experimental interven-
tion) indicate that the beneficial effects may in fact be 
inflated due to the unblinding effects of using an inert 
placebo [25].
Tricyclic antidepressants are associated with a broad 
spectrum of adverse effects, but the serious and non-seri-
ous adverse events associated with all types of tricyclic 
antidepressants have not been systematically assessed in 
adults with major depressive disorder. A recent network 
meta-analysis published in The Lancet in 2018 included 
placebo-controlled and head-to-head trials to assess the 
effects of 21 commonly used antidepressants, including 
two tricyclic antidepressants, amitriptyline and clomi-
pramine [21]. The results showed that antidepressants 
compared with placebo seemed to reduce depressive 
symptoms with a statistically significant effect (standard-
ised mean difference (SMD) 0.30, 95% credibility interval 
0.26 to 0.34) [21]. The results also showed that amitrip-
tyline was the most effective antidepressant for reducing 
depressive symptoms (odds ratio (OR) 2.30, 95% cred-
ibility interval 1.89 to 2.41), and that clomipramine was 
one of the least effective antidepressants for reducing 
depressive symptoms in the meta-analysis (OR 1.49, 95% 
symptoms, serious adverse events and quality of life. Secondary outcomes will be suicide or suicide-attempts and 
non-serious adverse events. If feasible, we will assess the intervention effects using random-effects and fixed-effect 
meta-analyses.
Discussion: Tricyclic antidepressants are recommended by clinical guidelines and frequently used worldwide in the 
treatment of major depressive disorder. There is a need for a thorough systematic review to provide the necessary 
background for weighing the benefits against the harms. This review will ultimately inform best practice in the treat-
ment of major depressive disorder.
Systematic review registration: PROSPERO CRD42 02122 6161.
Keywords: Antidepressants, Tricyclic antidepressants, Major depressive disorder, Beneficial effects, Adverse effects
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credibility interval 1.21 to 1.85) [21]. However, neither 
serious nor non-serious adverse events were assessed. 
Instead, the authors assessed lack of ‘acceptability’ (treat-
ment discontinuation measured by the proportion of 
participants who withdrew for any reason) and the pro-
portion of participants who dropped out early because of 
adverse effects [21]. Such data on withdrawals as surro-
gate markers for safety or tolerability should, however, be 
interpreted with caution due to a number of issues that 
include difficulty attributing reasons for discontinua-
tion, pressures on patients and investigators to reduce the 
number of withdrawals, and unblinding that often pre-
cedes decisions to withdraw [26].
A Cochrane review published in 2003 investigated 
effects of low dosage tricyclic antidepressants compared 
with placebo or standard dosage tricyclic antidepressants 
in the acute-phase treatment of depressive disorder [23]. 
Thirty-five trials (2013 participants) compared low dos-
age tricyclic antidepressants with placebo, and six trials 
(551 participants) compared low dosage tricyclic antide-
pressants with standard dosage tricyclic antidepressants 
[23]. The authors found that low dosage tricyclic anti-
depressants were more effective in reducing depressive 
symptoms than placebo, and that standard dosage tricy-
clic antidepressants were not significantly more effective 
in reducing depressive symptoms compared with low 
dosage tricyclic antidepressants [23]. Low dosage tricy-
clic antidepressants were found to be more likely than 
placebo to cause at least one adverse effect, and standard 
dosage was more likely than low dosage tricyclic antide-
pressants to cause dropouts due to adverse effects [23]. 
Serious adverse events, suicides and suicide attempts 
were not assessed. Additionally, this review did not com-
pare standard dosage tricyclic antidepressants with pla-
cebo, and not all types of tricyclic antidepressants were 
included [23].
A meta-analysis of 15 randomised clinical trials pub-
lished in 2005 assessed the efficacy and tolerability of 
tricyclic antidepressants and selective serotonin reup-
take inhibitors compared with placebo for treatment of 
depression in primary care [22]. The results showed that 
tricyclic antidepressants compared with placebo reduced 
depressive symptoms with a statistically significant effect 
(SMD − 0.42, 95% confidence interval − 0.55 to − 0.30) 
[22]. The authors also found that tricyclic antidepres-
sants increased the risk of withdrawal from the trial 
due to drug-related adverse events [22]. However, the 
meta-analysis only assessed drug-related adverse events 
(adverse reactions) and did not assess all adverse effects 
including serious adverse events. Furthermore, the risk of 
suicide and suicide attempts were not assessed, and the 
meta-analysis was limited by only including trials in a 
primary care setting [22].
Given the limitations of extant systematic reviews, we 
aim to investigate the beneficial effects and serious and 
non-serious adverse effects of tricyclic antidepressants 
for major depressive disorder in adults including both 
published and unpublished data. Our systematic review 
will take bias risk (systematic errors), play of chance (ran-
dom errors) and certainty of the findings into considera-
tion. This systematic review will be conducted as part of 
a larger project investigating the beneficial and harmful 
effects of all antidepressants for major depressive dis-
order [27]. In addition to this systematic review, we will 
also publish separate systematic reviews for selective 
serotonin reuptake inhibitors, duloxetine [28], venlafax-
ine and mirtazapine [27]. These systematic reviews will 
ultimately provide data for a systematic review investigat-
ing the effects of all antidepressants for major depressive 
disorder [27]. We chose to publish the present protocol 
and systematic review separately to investigate the effects 
of tricyclic antidepressants in more detail (i.e. more out-
comes) [27].
Methods
The present protocol has been registered in the PROS-
PERO database (CRD42021226161) and is reported in 
accordance with the reporting guidance provided in the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis Protocols (PRISMA-P) statement [29, 30] 
(see checklist in Additional file 1).
Criteria for considering trials for this review
Types of trials
We will include randomised clinical trials irrespective of 
trial design, setting, publication status, publication year 
and language. We will not include quasi-randomised tri-
als, cluster-randomised trials or non-randomised stud-
ies, as they are at greater risk of bias. By excluding such 
studies and trials we are, however, aware that we may 
miss some data on adverse effects, especially rare and late 
occurring adverse events.
Types of participants
Adults (as defined by trialists) with a primary diagnosis 
of major depressive disorder as defined by standardised 
diagnostic criteria such as the Diagnostic and Statisti-
cal Manual of Mental Disorders, Fifth Edition [1], Inter-
national Classification of Diseases, 10th Revision [31] 
or earlier versions of these diagnostic manuals. Major 
depressive disorder must be the primary diagnosis, and 
we will therefore not include trials randomising partici-
pants with a primary somatic diagnosis and comorbid 
major depressive disorder. Participants will be included 
irrespective of sex and comorbidities. If a trial reports 
data where only a subset of participants is eligible (e.g. 
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a combination of adolescents and adults), we will only 
include those that fulfil the inclusion criteria, and it 
therefore requires that data can be obtained for that spe-
cific group.
Types of interventions
As experimental intervention, we will include the follow-
ing tricyclic antidepressants: amineptine, amitriptyline, 
amoxapine, butriptyline, cianopramine, clomipramine, 
desipramine, demexiptiline, dibenzepin, dosulepin, 
dothiepin, doxepin, imipramine, iprindole, lofepramine, 
maprotiline, melitracen, metapramine, nortriptyline, 
noxiptiline, opipramol, protriptyline, tianeptine, trimi-
pramine and quinupramine [32] irrespective of dose and 
duration of administration. We will only include treat-
ment arms that use doses within the licenced dose range.
As control intervention, we will include: ‘active placebo’ 
(a matching placebo that produces noticeable and com-
parable adverse effects to tricyclic antidepressants that 
may convince the participant and blinded outcome asses-
sors that the participants are receiving an ‘active’ inter-
vention), placebo or no intervention, e.g. ‘waiting-list’.
Cointerventions
We will accept any co-intervention (e.g. other drug treat-
ment or psychotherapy), if the co-intervention is planned 




1. Depressive symptoms measured on the 17-item or 
21-item Hamilton Depression Rating Scale (HDRS) 
[33]. Where the 21-item scale is used, we will only 
include the data if the total score is only based on the 
first 17 items.
2. The proportion of participants with one or more 
serious adverse events. We will use the International 
Conference on Harmonization of technical require-
ments for registration of pharmaceuticals for human 
use—Good Clinical Practice (ICH-GCP) definition 
of a serious adverse event, which is any untoward 
medical occurrence that resulted in death, was life-
threatening, required hospitalisation or prolonging 
of existing hospitalisation and resulted in persistent 
or significant disability or jeopardised the participant 
[34]. If the trialists do not use the ICH-GCP defini-
tion, we will include the data if the trialists use the 
term ‘serious adverse event’. If the trialists do not use 
the ICH-GCP definition nor use the term serious 
adverse event, then we will also include the data pro-
vided the event clearly fulfils the ICH-GCP definition 
for a serious adverse event. We will secondly assess 
each serious adverse event separately (see below).
3. Quality of life (any valid continuous scale, e.g. the 
EQ-5D [35])
Secondary outcomes
1. The proportion of participants with either a suicide 
or a suicide-attempt (as defined by the trialists).
2. The proportion of participants with one or more 
non-serious adverse events (any adverse event not 
classified as serious). We will secondly assess each 
non-serious adverse event separately (see below).
Exploratory outcomes
1. Depressive symptoms measured on the Montgom-
ery-Asberg Depression Rating Scale (MADRS) [36], 
the Beck’s Depression Inventory (BDI) [37], or the 
6-item HDRS [38].
2. Individual serious adverse events.
3. Individual non-serious adverse events.
4. Suicidal ideation (any valid continuous scale).
5. The proportion of participants achieving response. 
We have defined response as a 50% reduction (from 
baseline) on either HDRS, MADRS or any other scale 
as used by trialists.
6. The proportion of participants achieving remission 
as defined by trialists.
Assessment time points
We will assess all our outcomes at end of treatment pri-
marily and at maximum follow-up secondarily.
Search methods for identification of trials
Electronic searches
We will search the Cochrane Central Register of Con-
trolled Trials (CENTRAL), Medical Literature Analy-
sis and Retrieval System Online (MEDLINE), Excerpta 
Medica Database (EMBASE), Latin American and Car-
ibbean Health Sciences Literature (LILACS), PsycINFO, 
Science Citation Index Expanded (SCI-EXPANDED), 
Social Sciences Citation Index (SSCI), Chinese Biomedi-
cal Literature Database (CBM), China Network Knowl-
edge Information (CNKI), Chinese Science Journal 
Database (VIP), Wafang Database, Conference Proceed-
ings Citation Index—Science (CPCI-S) and Conference 
Proceedings Citation Index—Social Science & Humani-
ties (CPCI-SSH) to identify relevant trials. We will search 
all databases from their inception to 12 May 2021. For 
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a detailed search strategy for all electronic databases, 
see Additional file  2. The search strategies for the Chi-
nese databases will be given at review stage. Trials will 
be included irrespective of language, publication status, 
publication year and publication type.
Searching other resources
The reference lists of relevant publications will be 
checked for any unidentified randomised trials. We will 
contact the authors of included trials by email asking 
for unpublished randomised trials. To identify unpub-
lished trials, we will also search clinical trial registers 
(ClinicalTrials.gov and the ICTRP Search Portal [39]), 
websites of pharmaceutical companies, websites of U.S. 
Food and Drug Administration (FDA), and European 
Medicines Agency (EMA). We will request FDA, EMA 
and national medicines agencies to provide all publicly 
releasable information about relevant randomised clini-
cal trials of antidepressants that were submitted for mar-
keting approval, including clinical study reports [26]. 
Additionally, we will hand search conference abstracts 
from psychiatry conferences for relevant trials. We will 
also include unpublished and grey literature trials if we 
identify these and assess relevant retraction statements 
and errata for included trials.
Data collection and analysis
We will perform and report the review following the 
recommendations stated in the Cochrane Handbook for 
Systematic Reviews of Interventions [26]. Analyses will 
be performed using Stata version 16.1 (StataCorp LLC, 
College Station, TX, USA) [40] and Trial Sequential 
Analysis [41, 42].
Selection of trials
Two review authors will independently screen titles and 
abstracts. We will retrieve all relevant full-text study 
reports/publications, and two review authors will inde-
pendently screen the full text to identify and record rea-
sons for exclusion of the ineligible trials. The two review 
authors will resolve any disagreement through discus-
sion, or, if required, they will consult with a third author.
Data extraction and management
Two authors will independently extract data from 
included trials. Disagreements will be resolved by dis-
cussion with a third author. The two review authors will 
assess duplicate publications and companion papers of a 
trial together to evaluate all available data simultaneously 
(maximise data extraction, correct bias assessment). 
We will contact the trial authors by email to obtain any 
additional data, which may not have been reported suf-
ficiently or at all in the publication.
Trial characteristics
We will extract the following data: bias risk compo-
nents (as defined below); trial design (parallel, factorial, 
or crossover); number of intervention groups; length 
of follow-up; estimation of sample size; inclusion and 
exclusion criteria; for-profit funding of trial and NCT/
EudraCT number.
Participant characteristics
We will extract the following data: number of ran-
domised participants; number of analysed participants; 
number of participants lost to follow-up/withdrawals/
crossover; age range (mean and standard deviation) and 
sex ratio.
Intervention characteristics
We will extract the following data: type of tricyclic antide-
pressant; dose of intervention; duration of intervention.
Control characteristics
We will extract the following data: type of control inter-
vention; dose of intervention; duration of intervention.
Outcomes
All outcomes listed above will be extracted from each 
randomised clinical trial, and we will identify if outcomes 
are incomplete or selectively reported according to the 
criteria described later in “incomplete outcome data” bias 
domain and “selective outcome reporting” bias domain.
Notes
We will search for information regarding industry fund-
ing of either personal or academic activities for each trial 
author. We will judge a publication at high risk of for-
profit bias if a trial is sponsored by the industry (includ-
ing trials partly sponsored by the industry, e.g. if the trial 
drug was sponsored by a medical company), or if just one 
author has any affiliation to the industry. We will note 
in the ‘characteristics of included studies’ table if out-
come data were not reported in a usable way. Two review 
authors will independently transfer data into the Stata file 
[40]. Disagreements will be resolved through discussion, 
or if required, we will consult with a third author.
Assessment of risk of bias in the included trials
Our bias risk assessment will be based on the Cochrane 
Risk of Bias tool—version 2 (RoB 2) as recommended 
in the Cochrane Handbook of Systematic Reviews of 
Interventions [26]. We will evaluate the methodology in 
respect of the following bias domains:
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Bias arising from the randomisation process 
• Low risk of bias: Allocation was adequately con-
cealed, AND baseline imbalances across intervention 
groups appear to be compatible with chance, AND 
an adequate (random or otherwise unpredictable) 
method was used to generate allocation sequence, 
OR there is no information about the method used to 
generate the allocation sequence.
• Some concerns: Allocation was adequately con-
cealed, AND there is a problem with the method of 
sequence generation, OR baseline imbalances sug-
gest a problem with the randomisation process, OR 
no information is provided about concealment of 
allocation, AND baseline imbalances across interven-
tion groups appear to be compatible with chance, OR 
no information to answer any of the signalling ques-
tions.
• High risk of bias: Allocation sequence was not con-
cealed, OR no information is provided about con-
cealment of allocation sequence, AND baseline 
imbalances suggest a problem with the randomisa-
tion process.
Bias due to deviation from intended interventions 
• Low risk of bias: Participants, carers and personnel 
were unaware of intervention groups during the trial, 
OR participants, carers or personnel were aware of 
intervention groups during the trial but any devia-
tions from intended intervention reflected usual 
practice, OR participants, carers or personnel were 
aware of intervention groups during the trial but any 
deviations from intended intervention were unlikely 
to impact on the outcome, AND no participants were 
analysed in the wrong intervention groups (that is, 
on the basis of intervention actually received rather 
than of randomised allocation).
• Some concerns: Participants, carers or personnel 
were aware of intervention groups and there is no 
information on whether there were deviations from 
usual practice that were likely to impact on the out-
come and were imbalanced between intervention 
groups, OR some participants were analysed in the 
wrong intervention groups (on the basis of interven-
tion actually received rather than of randomised allo-
cation) but there was little potential for a substantial 
impact on the estimated effect of intervention.
• High risk of bias: Participants, carers or person-
nel were aware of intervention groups, and there 
were deviations from intended interventions that 
were unbalanced between the intervention groups 
and likely to have affected the outcome, OR some 
participants were analysed in the wrong interven-
tion groups (on the basis of intervention actually 
received rather than of randomised allocation), and 
there was potential for a substantial impact on the 
estimated effect of intervention.
Bias due to missing outcome data 
• Low risk of bias: No missing data OR non-differen-
tial missing data (similar proportion of and similar 
reasons for missing data in compared groups) OR 
evidence of robustness of effect estimate to miss-
ing data (based on adequate statistical methods for 
handling missing data and sensitivity analysis).
• Some concerns: An unclear degree of missing data 
or unclear information on proportion and reasons 
for missingness in compared groups AND there 
is no evidence that the effect estimate is robust to 
missing data.
• High risk of bias: A high degree of missing data 
AND differential missing data (different proportion 
of or different reasons for missing data in compared 
groups) AND there is no evidence that the effect 
estimate is robust to missing data.
Bias in measurement of outcomes 
• Low risk of bias: The outcome assessors were una-
ware of the intervention received by study partici-
pants, OR the outcome assessors were aware of the 
intervention received by study participants, but the 
assessment of the outcome was unlikely to be influ-
enced by knowledge of the intervention received.
• Some concerns: There is no information available 
to determine whether the assessment of the out-
come is likely to be influenced by knowledge of the 
intervention received.
• High risk of bias: The assessment of the outcome 
was likely to be influenced by knowledge of the 
intervention received by study participants.
Bias arising from selective reporting of results 
• Low risk of bias: Reported outcome data are 
unlikely to have been selected, on the basis of the 
results, from multiple outcome measurements (e.g. 
scales, definitions, time points) within the outcome 
domain, and reported outcome data are unlikely to 
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have been selected, on the basis of the results, from 
multiple analyses of the data.
• Some concerns: There is insufficient information 
available to exclude the possibility that reported 
outcome data were selected, on the basis of the 
results, from multiple outcome measurements (e.g. 
scales, definitions, time points) within the outcome 
domain, or from multiple analyses of the data. Given 
that analysis intentions are often unavailable or not 
reported with sufficient detail, we anticipate that this 
will be the default judgement for most trials.
• High risk of bias: Reported outcome data are likely to 
have been selected, on the basis of the results, from 
multiple outcome measurements (e.g. scales, defini-
tions, time points) within the outcome domain, or 
from multiple analyses of the data (or both).
Overall assessment of risk of bias 
• Low risk of bias: The trial is judged to be at low risk 
of bias for all domains.
• High risk of bias: The trial is judged to be at high 
risk of bias or to be at some concerns in at least one 
domain. Our subgroup analysis will compare the 
intervention effect of trials at low risk of bias with tri-
als at high risk of bias, that is one or more domains at 
some concern or high risk of bias.
We will assess the domains ‘missing outcome data’, 
‘risk of bias in measurement of the outcome’ and ‘risk of 
bias in selection of the reported result’ for each outcome 
result. Thus, we can assess the bias risk for each outcome 
assessed in addition to each trial. Our primary conclu-
sions will be based on the results of our primary outcome 
results with overall low risk of bias. Both our primary and 
secondary results will be presented in the ‘Summary of 
Findings’ tables.
Differences between the protocol and the review
We will conduct the review according to this published 
protocol and report any deviations from it in the ‘Differ-
ences between the protocol and the review’ section of the 
systematic review.
Measurement of treatment effect
Dichotomous outcomes We will calculate risk ratios 
(RRs) with 95% confidence interval (CI) for dichoto-
mous outcomes, as well as the Trial Sequential Analysis-
adjusted CIs (see below).
Continuous outcomes We will calculate the mean differ-
ences (MDs) and consider calculating the SMD with 95% 
CI for continuous outcomes. We will also calculate Trial 
Sequential Analysis-adjusted CIs (see below).
Dealing with missing data
We will use intention-to-treat data if provided by the 
trialists [43]. We will, as the first option, contact all trial 
authors to obtain any relevant missing data (i.e. for data 
extraction and for assessment of risk of bias, as specified 
above).
Dichotomous outcomes We will not impute missing 
values for any outcomes in our primary analysis. In our 
sensitivity analyses (see paragraph below), we will impute 
data.
Continuous outcomes We will primarily analyse scores 
assessed at single time points. If only changes from 
baseline scores are reported, we will analyse the results 
together with follow-up scores [26]. If standard devia-
tions (SDs) are not reported, we will calculate the SDs 
using trial data, if possible. We will not use intention-to-
treat data if the original report did not contain such data. 
We will not impute missing values for any outcomes in 
our primary analysis. In our sensitivity analysis (see para-
graph below) for continuous outcomes, we will impute 
data.
Assessment of heterogeneity
We will primarily investigate forest plots to visually 
assess any sign of heterogeneity. We will secondly assess 
the presence of statistical heterogeneity by  chi2 test 
(threshold P < 0.10) and measure the quantities of hetero-
geneity by the I2 statistic [44, 45]. We will investigate pos-
sible heterogeneity through subgroup analyses. We may 
ultimately decide that a meta-analysis should be avoided 
[26].
Assessment of reporting biases
We will use a funnel plot to assess reporting bias if ten 
or more trials are included. We will visually inspect fun-
nel plots to assess the risk of small trial effects that could 
potentially reflect publication bias. We are aware of the 
limitations of a funnel plot (i.e. a funnel plot assesses bias 
due to small sample size). From this information, we will 
assess possible risk of publication bias. For dichotomous 
outcomes, we will test asymmetry with the Harbord test 
[46] if τ2 is less than 0.1 and with the Rücker test if τ2 is 
more than 0.1. For continuous outcomes, we will use the 
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regression asymmetry test [47] and the adjusted rank 
correlation [48].
Unit of analysis issues
We will only include randomised clinical trials. For tri-
als using crossover design, only data from the first period 
will be included [26, 49]. We will not include cluster ran-
domised trials. Where multiple trial arms are reported in 
a single trial, we will include only the relevant arms. For 
trials with multiple relevant experimental groups, we will 
either combine the groups (when considered subtypes of 
the same intervention) or divide the number of events 
and sample size of the control group (e.g. for two different 
types of tricyclic antidepressants). For continuous data, 
we will keep the main score [26]. In case of, for example, 
a 2 × 2 factorial design trial, the two groups receiving 
antidepressants will be considered experimental groups, 
whilst the two groups receiving ‘active placebo’, placebo 
or no intervention will be considered control groups.
Data synthesis
Meta‑analysis
We will undertake the meta-analysis according to the 
Cochrane Handbook for Systematic Reviews of Interven-
tions [26], Keus et al. [50] and our eight-step procedure 
suggested by Jakobsen et al. [51]. We will use the statisti-
cal software Stata version 16 to analyse data [40]. We will 
assess the intervention effects with both random-effects 
model meta-analyses (Hartung-Knapp-Sidik-Jonkman) 
[52] and fixed-effect model meta-analyses (Mantel–
Haenszel for dichotomous outcomes and inverse vari-
ance for continuous outcomes) [26, 53]. We will use the 
more conservative point estimate of the two [51]. The 
more conservative point estimate is the estimate with 
the highest P value. We assess a total of five primary and 
secondary outcomes, and we will therefore consider a P 
value of 0.016 or less as the threshold for statistical sig-
nificance [51]. We will investigate possible heterogeneity 
through subgroup analyses. We will use our eight-step 
procedure to assess if the thresholds for significance are 
crossed [51]. This eight-step procedure is comprised of 
the following steps: (1) obtain the 95% confidence inter-
vals and the P values from both fixed-effect and random-
effects meta-analyses and report the most conservative 
results as the main results; (2) explore the reasons behind 
substantial statistical heterogeneity using subgroup and 
sensitivity analyses (see step 6); (3) to take account of 
problems with multiplicity adjust the thresholds for sig-
nificance according to the number of primary outcomes 
(we will also adjust for secondary outcomes); (4) calculate 
required information sizes (≈ the a priori required num-
ber of participants for a meta-analysis to be conclusive) 
for all outcomes and analyse each outcome with Trial 
Sequential Analysis. Report whether the trial sequential 
monitoring boundaries for benefit, harm or futility are 
crossed; (5) calculate Bayes factors for all primary out-
comes; (6) use subgroup analyses and sensitivity analy-
ses to assess the potential impact of bias on the review 
results; (7) assess the risk of publication bias; (8) assess 
the clinical significance of the statistically significant 
review results [51].
Trial sequential analysis
Traditional meta-analysis runs the risk of random errors 
due to sparse data and repetitive testing of accumulating 
data when updating reviews. We wish to control the risks 
of type I and type II errors. We will therefore perform 
Trial Sequential Analysis on all outcomes, in order to 
calculate the required information size (that is, the num-
ber of participants needed in a meta-analysis to detect or 
reject a certain intervention effect) and the cumulative 
Z-curve’s breach of relevant trial sequential monitoring 
boundaries [41, 42, 54–60]. A more detailed description 
of Trial Sequential Analysis can be found in the manual 
[42] and at http:// www. ctu. dk/ tsa/. For dichotomous out-
comes, we will estimate the required information size 
based on the observed proportion of patients with an 
outcome in the control group (the cumulative propor-
tion of patients with an event in the control groups rela-
tive to all patients in the control groups), a relative risk 
reduction or a relative risk increase of 20%, an alpha of 
1.6% for all our outcomes, a beta of 10% and the observed 
diversity as suggested by the trials in the meta-analysis. 
For continuous outcomes, we will in the Trial Sequential 
Analysis use the observed standard deviation (SD) in the 
control group, a mean difference of three HDRS points 
when assessing depressive symptoms; otherwise, the 
observed SD/2, an alpha of 1.6% for all outcomes, a beta 
of 10%, and the observed diversity as suggested by the tri-
als in the meta-analysis.
Subgroup analysis and integration of heterogeneity
Subgroup analysis We will perform the following sub-
group analyses when analysing the primary outcomes 
(depressive symptoms, serious adverse events, quality of 
life).
• Trials at high risk of bias compared to trials at low 
risk of bias
• Trials without for profit bias compared to trials at 
unknown or known risk of for profit bias [61]
• Types of tricyclic antidepressant agents (aminept-
ine, amitriptyline, amoxapine, butriptyline, ciano-
pramine, clomipramine, desipramine, demexiptiline, 
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dibenzepin, dosulepin, dothiepin, doxepin, imipra-
mine, iprindole, lofepramine, maprotiline, melitra-
cen, metapramine, nortriptyline, noxiptiline, opipra-
mol, protriptyline, tianeptine, trimipramine and 
quinupramine)
• Types of comparator (‘active placebo’, placebo no 
intervention)
• Age groups (18 to 24 years, 25 to 64 years, ≥ 65 years)
• Type of definition used for serious adverse events. 
This may be the ICH-GCP definition, the term ‘seri-
ous adverse events’, or data that clearly fulfils the 
ICH-GCP definition but is not referred to by the 
abovementioned definitions.
• Type of diagnostic criteria (operationalised criteria 
versus non-operationalised criteria).
We will use the formal test for subgroup interactions in 
Stata [40].
Sensitivity analysis To assess the potential impact of the 
missing data for dichotomous outcomes, we will perform 
the two following sensitivity analyses on both the pri-
mary and secondary dichotomous outcomes.
‘Best–worst-case’ scenario: We will assume that all par-
ticipants lost to follow-up in the antidepressant group 
survived, had no serious adverse events, had no suicides 
or suicide attempts and had no non-serious adverse 
events, and that all those participants lost to follow-up in 
the control group did not survive, had a serious adverse 
event, died by suicide or had a suicide attempt and had a 
non-serious adverse event.
‘Worst-best-case’ scenario: We will assume that all par-
ticipants lost to follow-up in the antidepressant group did 
not survive, had a serious adverse event, died by suicide 
or had a suicide attempt and had a non-serious adverse 
event, and that all those participants lost to follow-up 
in the control group survived, had no serious adverse 
events, had no suicides or suicide attempts and had no 
non-serious adverse events.
We will present results of both scenarios in our review. 
When analysing depressive symptoms and quality of life, 
a ‘beneficial outcome’ will be the group mean plus two 
SDs (we will secondly use one SD in another sensitivity 
analysis) of the group mean and a ‘harmful outcome’ will 
be the group mean minus two SDs (we will secondly use 
one SD in another sensitivity analysis) of the group mean 
[51]. To assess the potential impact of missing SDs for 
continuous outcomes, we will perform the following sen-
sitivity analysis:
Where SDs are missing and it is not possible to calculate 
them, we will impute SDs from trials with similar popu-
lations and low risk of bias. If we find no such trials, we 
will impute SDs from trials with a similar population. 
As the final option, we will impute the mean SD from all 
included trials.
We will present results of this scenario in our review. 
Other post hoc sensitivity analyses might be warranted if 
unexpected clinical or statistical heterogeneity is identi-
fied during the analysis of the review results [51].
Summary of findings table We will create a summary of 
findings table for each comparison (tricyclic antidepres-
sants vs. ‘active placebo’, placebo and no intervention) 
including each of the prespecified primary and second-
ary outcomes (depressive symptoms, serious adverse 
events, quality of life, suicides or suicide attempts, non-
serious adverse events). We will use the Grading of Rec-
ommendations, Assessment, Development and Evalua-
tions (GRADE) considerations (bias risk, heterogeneity, 
imprecision, indirectness and publication bias) to assess 
the quality of a body of evidence [51, 62–64]. We will 
assess imprecision using Trial Sequential Analysis. We 
will justify all decisions to downgrade the quality of evi-
dence using footnotes, and we will make comments to 
aid the reader’s understanding of the review where neces-
sary. Firstly, we will present our results in the summary 
of findings table based on the results from the trials with 
overall low risk of bias, and secondly, we will present the 
results based on all trials.
Discussion
This protocol aims to assess the beneficial and harm-
ful effects of tricyclic antidepressants versus ‘active pla-
cebo’, placebo or no intervention in adults with major 
depressive disorder. Primary outcomes will be depressive 
symptoms, serious adverse events and quality of life. Sec-
ondary outcomes will be suicide or suicide attempts, and 
non-serious adverse events.
Our protocol has several strengths. The predefined 
methodology is based on Cochrane methodology [26], 
Keus et  al. [50], our eight-step assessment suggested 
by Jakobsen et  al. [51], Trial Sequential Analysis [41] 
and GRADE assessment [62–64]. Hence, this proto-
col considers both risks of random errors and risks of 
systematic errors as well as risks of external validity, 
heterogeneity and risks of publication bias [51]. Fur-
thermore, we increase the statistical power by pooling 
all tricyclic antidepressants as the experimental inter-
vention. This inclusiveness also allows us to assess the 
different tricyclic antidepressants relative effects to 
Page 10 of 12Jørgensen et al. Syst Rev          (2021) 10:227 
the comparators. Moreover, we will include data from 
both unpublished and published trials as well as clini-
cal study reports [26]. The latter should secure a fairer 
comparison of benefits and harms [26].
Our protocol also has limitations. The primary limi-
tation is the potential for high statistical heterogeneity 
due to the inclusion of various tricyclic antidepressants 
as the experimental intervention. To minimise this lim-
itation, we will carefully look for signs of heterogeneity 
and ultimately decide if data ought to be meta-analysed, 
and we have planned several sensitivity analyses and 
subgroup analyses. Another limitation is the large num-
ber of comparisons which increases the risks of type 1 
errors. We have adjusted our thresholds for significance 
according to the number of primary and secondary 
outcomes, but we have not adjusted our thresholds for 
significance according to the total number of compari-
sons (e.g. subgroup analyses and sensitivity analyses). 
Moreover, we expect inadequate reporting of harmful 
effects in the included trials, which increases the risk of 
underestimation of harmful effects [26]. Although we 
will request unpublished randomised trials, we expect 
challenges with obtaining the unpublished data. Finally, 
we expect short treatment and follow-up periods which 
may not accurately mimic how antidepressants are used 
in clinical practice [65, 66].
Although tricyclic antidepressants have previously 
been investigated in systematic reviews, no former 
review has systematically assessed the beneficial and 
harmful effects of all types of tricyclic antidepressants 
compared with ‘active placebo’, placebo or no interven-
tion. Since tricyclic antidepressants are recommended 
by clinical guidelines and frequently used worldwide 
[17, 19, 67], there is a need for a systematic review 
assessing the benefits and the harms in treatment of 
adults with major depressive disorder. The review will 
ultimately inform best practice in the treatment of 
major depressive disorder.
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